IDEA

Regimen

Experimental
3 months of FOLFOX or CAPOX
Control
6 months of FOLFOX or CAPOX (same regimen)

Population

Stage III colon cancer after curative resection; pooled analysis of 6 RCTs (N=12,834), comparing 3 vs 6 months adjuvant oxaliplatin-based chemotherapy.

Key finding

Overall noninferiority of 3 vs 6 months not confirmed (HR 1.07). CAPOX 3 months noninferior (HR 0.95, 95% CI 0.85-1.06); FOLFOX 3 months inferior (HR 1.16). Low-risk (T1-3 N1): 3-year DFS 83.1% vs 83.3% (3 vs 6 mo); High-risk (T4/N2): 6 months superior (64.4% vs 62.7%). Neurotoxicity markedly reduced with 3 months.

Source: PMID 29590544

Timeline

    Guideline citations

    • NCCN Colon (p.65)
    • NCCN Rectal (p.127)